Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Clinical trial NCT02130193 · COMPLETED

Trial details

NCT number

NCT02130193

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2014-02-13

Primary completion

2016-08-29

Enrollment

102

View on ClinicalTrials.gov